Drug Profile
Research programme: glycoimmune checkpoint inhibitors - Palleon Pharmaceuticals
Alternative Names: Anti-Siglec-9 antibodies - Palleon Pharmaceuticals; EAGLE-Her2; glycoimmune checkpoint inhibitors - Palleon Pharmaceuticals; Sialidase-PD-L1; Sialidase–Her2Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Howard Hughes Medical Institute; Stanford University; University of Dundee
- Developer Palleon Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Enzymes; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Membrane glycoprotein modulators; Neuraminidase replacements; SIGLEC9 protein modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation
Most Recent Events
- 14 Oct 2022 Palleon Pharmaceuticals has patent protection for use of antibody sialidase conjugates in USA
- 24 Mar 2021 Preclinical trials in Cancer in USA (Parenteral) before March 2021 (Palleon Pharmaceuticals' pipeline, March 2021)
- 17 Sep 2020 Palleon Pharmaceuticals plans clinical trials for Cancer in 2021